title: Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816.
abstract: Thiopyrano[2,3,4-c,d]indoles are a new class of 5-lipoxygenase (5-LO) inhibitors. SAR studies have demonstrated that the thiopyran ring, the 5-phenylpyridine substituent, and an acidic functional group on a four-carbon C-2 side chain are all required for optimal inhibitor potency. In contrast, the indolic nitrogen may be substituted with a variety of lipophilic groups. As a result of the SAR investigation, 44 (L-691,816; 5-[3-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy ]- 4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpro pyl]-1H- tetrazole) has been identified as a potent inhibitor of the 5-LO reaction both in vitro and in a range of in vivo models. Compound 44 inhibits 5-HPETE production by both rat and human 5-LO and LTB4 synthesis in human PMN leukocytes (IC50s 16, 75, and 10 nM, respectively). The mechanism of inhibition of 5-LO activity by compound 44 appears to involve the formation of a reversible deadend complex with the enzyme and does not involve reduction of the nonheme iron of 5-LO. Compound 44 is highly selective for 5-LO when compared to the inhibition of human FLAP, porcine 12-LO, and also ram seminal vesicle cyclooxygenase. In addition, 44 is orally active in a rat pleurisy model (inhibition of LTB4, ED50 = 1.9 mg/kg; 8 h pretreatment) as well as in the hyperreactive rat model of antigen-induced dyspnea (ED50 = 0.1 mg/kg; 2-h pretreatment). Excellent functional activity was also observed in both the conscious allergic monkey and sheep models of asthma. In the latter case, the functional activity observed correlated with the inhibition of urinary LTE4 excretion.
authors.affiliation: Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Quebec, Canada.
authors.forename: J H
authors.initials: JH
authors.lastname: Hutchinson
authors.forename: D
authors.initials: D
authors.lastname: Riendeau
authors.forename: C
authors.initials: C
authors.lastname: Brideau
authors.forename: C
authors.initials: C
authors.lastname: Chan
authors.forename: D
authors.initials: D
authors.lastname: Delorme
authors.forename: D
authors.initials: D
authors.lastname: Denis
authors.forename: J P
authors.initials: JP
authors.lastname: Falgueyret
authors.forename: R
authors.initials: R
authors.lastname: Fortin
authors.forename: J
authors.initials: J
authors.lastname: Guay
authors.forename: P
authors.initials: P
authors.lastname: Hamel
mesh_terms: D000284:Administration, Oral; D000818:Animals; D006801:Humans; D007211:Indoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D007975:Leukotriene B4 / Q000096:biosynthesis; D008084:Lipoxygenase / Q000096:biosynthesis / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D008297:Male; D009504:Neutrophils / Q000187:drug effects*; D011725:Pyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012453:Saimiri; D012756:Sheep; D013329:Structure-Activity Relationship
chemical_list: D007211:Indoles; D016859:Lipoxygenase Inhibitors; D011725:Pyridines; C083376:L 691816; D007975:Leukotriene B4; D008084:Lipoxygenase